Investor Relations

Company Overview

IR-MED Inc.’s patented spectrographic AI-based technology platform brings biomarker profiling to point of care devices. Providing healthcare professionals with non-invasive, skin tone agnostic, real-time data-driven analysis of blood and tissue to assess medical conditions, the Company aims to change treatment paradigms and economics in muti-billion markets.

PressureSafe™️, FDA listed, leading product, is a handheld decision support scanner that assess pressure injuries before skin breakage with ~90% accuracy, creating a novel solution to a $26.8 billion problem and driving healthcare equality for people of all skin tones. Despite being a highly preventable condition, 2.5 million people get pressure injuries each year. 60,000 deaths annually in the U.S are directly attributed to pressure injuries, the 2nd most common lawsuit after wrongful death.

IR-MED holds patents protecting its technology and innovations in the noninvasive tissue assessment. Future indications for IR-MED’s technology are planned for additional tissue and skin indications, diabetic foot ulcer (DFU), ear infections, and therapeutic drug monitoring.